Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo.
Phase of Trial: Phase IV
Latest Information Update: 30 Jan 2014
Price : $35 *
At a glance
- Drugs Eplerenone (Primary)
- Indications Heart failure; Hypertension
- Focus Pharmacodynamics
- Acronyms eplerenone-01
- 30 Jan 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 31 Oct 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 19 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01837108)